Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Last --
Change Today 0.00 / 0.00%
Volume 0.0
1112 On Other Exchanges
1112 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

biostime international holdi (1112) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOSTIME INTERNATIONAL HOLDI (1112)

Related News

No related news articles were found.

biostime international holdi (1112) Related Businessweek News

No Related Businessweek News Found

biostime international holdi (1112) Details

Biostime International Holdings Limited, an investment holding company, provides pediatric nutritional and baby care products to mothers primarily in the People’s Republic of China. The company operates through four segments: Infant Formulas, Probiotic Supplements, Dried Baby Food and Nutrition Supplements, and Baby Care Products. The Infant Formulas segment produces infant formulas for children under seven years old and milk formulas for expectant and nursing mothers. The Probiotic Supplements segment offers probiotic supplements in the form of sachets, capsules, and tablets for infants, children, and expectant mothers. The Dried Baby Food and Nutrition Supplements segment engages in the production of dried baby food products made from natural foods for infants and young children; microencapsulated milk calcium chewable tablets and DHA chews/soft capsules for children, and pregnant and lactating mothers. The Baby Care Products segment provides baby care products for infants and children, including baby diapers and toiletry kits, as well as personal care products for nursing mothers, such as nursing pads. Biostime International Holdings Limited is also involved in the wholesale, retail, import, and export of personal care products for infants; trading of infant food and nutritional products; early childhood education advisory business; and trading of related baby supplies. It sells its products and services through distributors under the Biostime, Adimil, BMcare, and Parenting Power brands. The company was founded in 1999 and is headquartered in Guangzhou, China. Biostime International Holdings Limited is a subsidiary of Biostime Pharmaceuticals (China) Limited.

3,000 Employees
Last Reported Date: 08/27/15
Founded in 1999

biostime international holdi (1112) Top Compensated Officers

Chairman, Chief Executive Officer, Chairman o...
Total Annual Compensation: CNY9.1M
Compensation as of Fiscal Year 2014.

biostime international holdi (1112) Key Developments

Biostime International Appoints Radek Sali as Executive Director

Biostime International has appointed Radek Sali as Executive Director. The effective date is January 21, 2016.

Biostime International Holdings Limited Announces Change of Executive Director

The board of directors of Biostime International Holdings Limited announced that Ms. Kong Qingjuan has tendered resignation to the Board as an executive director of the company with effect from 21 January 2016 due to devote more time to pursue her personal engagements. The board also announced that Mr. Radek Sali has been appointed as executive director of the company with effect from 21 January 2016. Mr. Sali is currently the chief executive officer and a director of Swisse Wellness Group Pty Ltd.

Biostime International Holdings Limited Provides Earnings Guidance for Nine Months Ended September 30, 2015

Biostime International Holdings Limited provided earnings guidance for nine months ended September 30, 2015. For the period, the company expects decrease in profit of the Group for the year ending 31 December 2015 as compared with the corresponding period last year is primarily due to: the sales of the newly launched SN-2 PLUS Balanced Formula series impacted by the longer time needed to clear away the previous Biostime branded infant formulas series inventories; the marketing and promotional expenses incurred in connection with the launch of SN-2 PLUS Balanced Formula series; the non-recurring expenses such as transaction costs, finance cost and foreign exchange loss incurred in relation to the acquisition of Swisse; and the non-recurring expense incurred in connection with the integration of the previous Biostime Business Unit, Adimil Business Unit and BMcare Business Unit into a Baby Nutrition and Care Business Unit.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
1112:HK $21.65 HKD -1.25

1112 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott India Ltd 4,814 INR -30.40
Inner Mongolia Yili Industrial Group Co Ltd CNY13.36 CNY -0.09
Mead Johnson Nutrition Co $69.88 USD +1.96
Synutra International Inc $4.95 USD -0.23
Yakult Honsha Co Ltd ¥5,440 JPY -40.00
View Industry Companies

Industry Analysis


Industry Average

Valuation 1112 Industry Range
Price/Earnings 15.1x
Price/Sales 2.3x
Price/Book 3.5x
Price/Cash Flow 15.5x
TEV/Sales 0.9x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact BIOSTIME INTERNATIONAL HOLDI, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at